Nasdaq
$14.58▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $865.3MShares out 59.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
3- 9.30Pre-market26.09.30 20:138-KKey event#●●●#●●●#●●●
Jade Biosciences, Inc.Bullish
Jade Biosciences announced preclinical data for JADE301, a monoclonal antibody in development for dermatomyositis, demonstrating superior affinity and potency compared to the comparator. The company expects to initiate a Phase 1 clinical trial in 24 healthy volunteers in the fourth quarter of 2026.…more
$14.58+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.10Pre-market26.08.10 20:2110-QEarnings
Jade Biosciences, Inc.
Jade Biosciences는 2026년 6월 29일 Paragon Therapeutics와 특정 항체 표적에 대한 독점 라이선스 계약을 체결했습니다. 또한 회사는 2025년 및 2026년 주식 인센티브 플랜을 도입하여 임직원 대상 스톡옵션 부여 근거를 마련했습니다.…more
$14.58+0.00%vs prev closeView filingShare - 8.10Pre-market26.08.10 20:138-KKey event
Jade Biosciences, Inc.
제이드 바이오사이언스는 2026년 2분기 실적 발표를 통해 5,576만 달러의 순손실을 기록했으며, 6월 30일 기준 4억 6,120만 달러의 현금 및 투자 자산을 보유하여 2028년 4분기까지 운영 자금을 확보했습니다. 주요 파이프라인인 JADE101의 임상 1상에서 긍정적인 중간 데이터를 확인했고, 2027년 상반기 임상 3상 진입을 계획하고 있습니다.…more
$14.58+0.00%vs prev closeView filingShare
2 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 20:00#●●●#●●●#●●●
Jade Biosciences Accelerates JADE101 Phase 3 Trial for IgA Nephropathy
Jade Biosciences announced at the ASN Kidney Week 2026 that it will accelerate the initiation of its Phase 3 clinical trial for JADE101 to the fourth quarter of 2026. The company also provided an updated timeline for interim data from its ongoing Phase 2 study, expected in the second quarter of 2027.…more
$14.58+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.30Pre-market26.09.30 20:00
●●●●●●●● ●●●●● ●●●●●●
Jade Biosciences reported positive preclinical data for its dermatomyositis candidate JADE301, highlighting its potential for infrequent dosing and superior potency. The company plans to initiate a Phase 1 clinical trial in the fourth quarter of 2026.…more
$14.58+0.00%vs prev close - 9.1Pre-market26.09.01 20:00
●●●●●●●● ●●●●● ●●●●●●
Jade Biosciences announced its participation in several upcoming healthcare and biopharma investor conferences throughout September. The management team will host fireside chats and one-on-one meetings to discuss the company's clinical pipeline.…more
$14.58+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report